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Edited by Robert BaroukiAbstract Resistin, a hormone secreted by adipocytes, is sug-
gested to be an important link between obesity and diabetes.
The aim of this study was to evaluate the regulatory eﬀect of
estrogen on adipocyte resistin gene expression in ovariectomized
(OVX) rats and in isolated rat adipocytes in vitro. Subcutaneous
injection of estradiol benzoate reduced resistin mRNA levels
in adipocytes isolated from the inguinal, parametrial, perirenal,
retroperitoneal, or periovarian fat deposits of OVX rats, while
an in vitro study showed that estradiol treatment decreased res-
istin mRNA levels in cultured rat periovarian fat adipocytes. Re-
sults of Western blotting analysis also showed that estrogen
decreased adipose resistin contents in vivo and in vitro. These
data suggest that estrogen is a pivotal negative regulator of res-
istin gene expression.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Resistin, a 12.5 kDa cysteine-rich polypeptide speciﬁcally se-
creted by adipocytes [1], belongs to a multigene family termed
resistin-like molecules (RELMs) or ‘‘found in inﬂammatory
zone’’ (FIZZ) proteins [2,3]. Resistin gene expression increases
markedly during the diﬀerentiation of 3T3-L1 cells and pri-
mary preadipocytes into adipocytes [1,4]. Serum resistin levels
are signiﬁcantly elevated in insulin-resistant mice and in mice
which are genetically obese or obese due to a high fat diet
(HFD) [1]. Immunoneutralization of endogenous resistin sig-
niﬁcantly improves insulin sensitivity in diet-induced obese
mice, while administration of recombinant resistin impairs glu-
cose tolerance in C57B1/6J mice in vivo [1]. In addition, resi-
stin gene expression is downregulated in animals treated with*Corresponding author. Fax: +886 2 28264049.
E-mail address: ccjuan@ym.edu.tw (C.-C. Juan).
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drugs with an insulin-sensitizing action [1]. These ﬁndings sug-
gest that resistin serves as a hormonal link between obesity and
insulin resistance. In a human study, resistin mRNA levels in
adipose tissue were increased in morbidly obese humans com-
pared to lean control subjects [5]. A genetic epidemiological
study of Caucasian families suggested that single nucleotide
polymorphisms in the resistin gene promoter region may alter
the negative correlation between the BMI and the insulin sen-
sitivity index in non-diabetic family members of type 2 diabet-
ics [6]. We recently developed a new method for production of
bioactive recombinant resistin in Escherichia coli, carried out a
structural characterization of the product, and found that it
dose-dependently antagonized insulin-mediated glucose up-
take in 3T3-L1 adipocytes [7]. Thus, resistin may play an
important role in modulation of insulin sensitivity.
To examine the possible pathogenic role of resistin in diabe-
tes and obesity, it is important to study the endocrine mecha-
nisms that regulate resistin expression and secretion. Several
studies have shown that resistin expression is regulated by hor-
mones, including glucocorticoids [8], endothelin-1 [9], growth
hormone [10], thyroid hormone [11], and tumor necrosis fac-
tor-a [12]. Adipose resistin mRNA levels are higher in male
rats than in female rats [11] and testosterone increases adipose
tissue resistin mRNA levels in male rats [11,13]. In addition,
pituitary resistin mRNA levels are also signiﬁcantly higher in
untreated male mice compared to females and testosterone
treatment of male mice, but not females, increases resistin
mRNA levels [14]. These observations suggest that another
sex hormone(s) may contribute to the gender diﬀerence in res-
istin expression, estrogen being a possible candidate. Eﬀects of
estrogen on adipocytokine secretion have been demonstrated
in several studies. Estrogen stimulates leptin secretion both
in vitro and in vivo [15]. In addition, ovariectomy does not
interfere with the pubertal rise in adiponectin in infant mice,
but increases adiponectin mRNA and protein levels in adults,
while estrogen decreases adiponectin mRNA and protein levels
in mice in vivo and in 3T3-L1 adipocytes in vitro [16]. These
ﬁndings indicate that estrogen may play an important role in
the physiological modulation of adipocytokines. However,
there are no data on the eﬀect of estrogen on resistin geneblished by Elsevier B.V. All rights reserved.
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in the ovariectomized (OVX) rat model, the eﬀect of in vivo
estrogen administration on resistin mRNA levels in adipocytes
from various fat deposits and (2) to determine whether in vitro
estrogen treatment of adipocytes isolated from rat periovarian
fat deposits could directly modulate resistin mRNA levels.2. Materials and methods
2.1. Experimental animals and in vivo study of protocol
Female Sprague–Dawley rats weighing 250–300 g were purchased
from a local breeder and housed in a temperature-controlled room
(22 ± 2 C) with 14 h of artiﬁcial illumination daily (6.00–20.00 h) with
food and water available ad libitum. OVX rats were used to study the
in vivo eﬀects of estrogen (estradiol benzoate; EB). All animals were
bilaterally ovariectomized under anesthesia. After a 2 week recovery
period, the OVX rats were divided into two groups and injected subcu-
taneously with either EB (25 lg/kg BW/day; n = 7) or vehicle (n = 7)
for three days, then decapitated the next day. A blood sample was col-
lected from each rat after decapitation and the serum separated by cen-
trifugation and stored at 20 C until assayed. Resistin mRNA levels
in adipocytes from the inguinal (IG), perirenal (PR), parametrial (PM),
retroperitoneal (RP), and periovarian (PO) adipose tissue were deter-
mined. All procedures were carried out in accordance with the Taiwan
Government Guide for the Care and Use of Laboratory Animals, and
the research protocol was approved by the animal welfare committee
of the National Yang-Ming University.
2.2. In vitro culture of rat adipocytes
Adipocytes isolated from the PO adipose tissue of untreated female
rats (no OVX, no drug treatment) weighing 250–300 g were precul-
tured for 5 h in Dulbeccos modiﬁed Eagles medium/Hams F12 con-
taining 20 lg/ml of bovine serum albumin (BSA), 20 mM HEPES,
0.1 lg/l of sodium selenite and 4.88 mg/l of ethanolamine at 37 C in
95% air and 5% CO2 [17]. The concentration of the adipocyte suspen-
sion was then adjusted to 5 · 105 cell/ml in the same medium and 10 ml
aliquots added to several ﬂasks. The cells in one ﬂask served as the un-
treated control, while the others were incubated either with 107 M EB
for diﬀerent time periods or with diﬀerent concentrations of EB for
24 h, then the medium was removed from beneath the adipocyte layer
and the cells transferred to tubes for a brief gentle centrifugation to re-
move any residual medium before total RNA was extracted.
2.3. Adipocyte isolation
IG, PR, PM, RP, and PO adipose tissue from each individual rat
was excised, weighed, and used to prepare adipocytes as described
by Rodbell [18] with minor modiﬁcations. The adipose tissue was ﬁnely
minced, then a cell suspension was prepared by gentle shaking for
60 min at 37 C in Krebs–Ringer bicarbonate (KRB) buﬀer containing
1 mmol/l of pyruvate, 1% BSA, and 0.1% collagenase. The cell suspen-
sion was ﬁltered through a 400 lm nylon mesh and centrifuged at
100 · g for 1 min at room temperature, then the supernatant was har-
vested and washed three times with 50 ml of KRB buﬀer containing
1 mmol/l of pyruvate and 1% BSA. To count the cells, an aliquot of
diluted cell suspension was ﬁxed overnight in collidine buﬀer contain-
ing 2% osmium tetroxide prior to microscopic photography.
2.4. RNA extraction
Total RNA was extracted from adipocytes isolated from each indi-
vidual rat using a Tri Reagent kit (Sigma–Aldrich, Inc., St. Louis,
MO). The integrity of the RNA was examined by 1% agarose gel elec-
trophoresis and its concentration determined by the UV absorbance at
260 nm (Genequant RNA/DNA calculator; Pharmacia, LKB Bio-
chrom, UK).2.5. Northern blotting
Northern blotting was carried out according to a standard proce-
dure as described previously [19]. 32P-labeled full-length rat resistin
cDNA and control glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA (1.1 kb, from Clontech, Palo Alto, CA) hybridiza-tion probes were prepared using the random priming DNA labeling
system. After hybridization, the signals were quantiﬁed by densitome-
try and the signals for the two resistin mRNAs (1.4 and 0.8 kb, due to
diﬀerent sizes of the 3 0-untranslated region) summed and normalized
to that of the corresponding GAPDH mRNA band.
2.6. Western blotting
Whole cell lysate was made by sonication in lysis buﬀer (1% Triton
X-100, 50 mM KCl, 25 mM HEPES, pH 7.8, 10 lg/ml leupeptin,
20 lg/ml aprotinin, 125 lM dithiothreitol, and 1 mM phenylmethylsul-
fonyl ﬂuoride). Samples (100 lg of total protein) in 50 ll of Laemmli
sample buﬀer were boiled for 10 min and resolved on 15% mini-
SDS–PAGE. The contents of the gel were then transferred onto poly-
vinylidene diﬂuoride membrane. The membrane was pre-blotted in 5%
skimmed milk in phosphate-buﬀered saline (PBS) for 30 min at room
temperature and then immunoblotted with anti-resistin (Linco Re-
search, Inc., St. Charles, MO) or anti-a-tubulin (Sigma–Aldrich) anti-
body for 24 h at 4 C followed by horseradish peroxidase-conjugated
secondary antibody for 60 min at room temperature, followed by rev-
elation with chemiluminescence reagent (Amersham Biosciences,
Buckinghamshire, England).
2.7. Measurement of serum glucose, insulin, and estradiol
Serum glucose concentrations were measured using a glucose ana-
lyzer (Model 23A, Yellow Springs Instrument, Yellow Springs, OH,
USA). Serum insulin and estradiol concentrations were measured
using commercial kits (Mercodia AB, Uppsala, Sweden; R&D systems
Inc., Minneapolis, MN, USA).
2.8. Measurement of the insulin resistance indices
The fasting glucose to insulin ratio (G0/I0) was measured as de-
scribed previously [20]. The homeostasis model assessment of insulin
resistance (HOMA-IR) value was calculated as: fasting glucose
(mmol/l) · fasting insulin (lIU/l)/22.5 [21].
2.9. Statistical analysis
All results are expressed as means ± S.D. Diﬀerences between
groups were analyzed using Students t test with a P value <0.05 being
considered signiﬁcant.3. Results
3.1. Basic data and biochemical parameters
No signiﬁcant diﬀerence was observed in the body weight of
OVX and EB-treated OVX (OVX + EB) rats (286 ± 39.6 vs.
278 ± 37.6 g). Serum estradiol levels were signiﬁcantly higher
in OVX + EB rats than in OVX rats (Table 1, P < 0.05), as
was uterine weight (43 ± 0.8 vs. 19 ± 0.2 mg, P < 0.0001).
There was no diﬀerence in fasting serum glucose levels between
the two groups, but the fasting serum insulin concentration
was signiﬁcantly higher in OVX + EB rats than in OVX rats
(Table 1), suggesting that EB administration induced a hyper-
insulinemic status in OVX rats. The changes in the G0/I0 and
HOMA-IR (Table 1) also indicated that OVX + EB rats were
more insulin-resistant than OVX rats.
3.2. Estrogen decreases resistin mRNA levels in adipocytes
from various anatomical sites in OVX rats
The eﬀect of estrogen on adipose resistin mRNA levels, eval-
uated by Northern blotting, was examined in vivo in OVX and
OVX + EB rats. Fig. 1, a representative Northern blot of PM
adipocytes using a resistin-speciﬁc probe, shows two tran-
scripts of 0.8 and 1.4 kb in length, the same sizes reported
previously for rat resistin [4], and that resistin mRNA levels
were lower in PM adipocytes isolated from OVX + EB rats
than in those isolated from OVX rats. Fig. 2 shows the results
Table 1
Serum levels of estradiol, glucose, and insulin and insulin resistance
indices in OVX and OVX + EB rats
Group OVX OVX + EB P
Estradiol (pg/ml) 15 ± 3.1 202 ± 4.8 0.019
Glucose (mg/dl) 128 ± 10.3 125 ± 12.9 NS
Insulin (lU/ml) 14 ± 6.9 28 ± 8.8 0.006
G0/I0 11 ± 5.4 5 ± 1.2 0.019
HOMA-IR 4 ± 2.3 9 ± 3.6 0.018
G0/I0: fasting glucose-to-insulin ratio.
HOMA-IR: Homeostasis model insulin resistance index.
A P value <0.05 was taken as signiﬁcant.
Fig. 1. Resistin mRNA levels are lower in PM adipocytes from
OVX + EB rats than in those from OVX rats. Total RNA isolated
from PM adipocytes of OVX and OVX + EB rats was subjected to
Northern blotting (15 lg RNA per lane) using rat resistin and
GAPDH probes. The ﬁgure shows a Northern blot and a picture of
the ethidium bromide-stained gel to assess the amount and quality of
the RNA; this result is representative of those of three separate
experiments. Two rat resistin mRNAs with sizes of 1.4 and 0.8 kb are
seen due to diﬀerences in the 3 0-untranslated region.
Fig. 2. Resistin gene expression as a function of the adipose tissue site.
Total RNA was isolated from IG (A), PM (B), PR (C), RP (D), or PO
(E) adipocytes and resistin mRNA levels measured by Northern
blotting and densitometric analysis, as described in Section 2, and
normalized to the GAPDH mRNA levels. The results are
means ± S.D. for seven rats. *P < 0.05 compared to the OVX group.
Fig. 3. Resistin mRNA levels in rat periovarian adipocytes are
reduced by in vitro estradiol treatment. Resistin mRNA levels in
adipocytes after in vitro exposure to 107 M estradiol for 4, 8, or 24 h
(A), or to 1012, 1010, 108, 106 M of estradiol for 24 h (B). The
results are means ± S.D. for four separate experiments, each using
pooled adipocytes from six rats. *P < 0.05 compared to the control
group.
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levels in adipose tissue from the IG, PM, PR, RP, and PO fat
deposits. In OVX rats, resistin mRNA levels in IG-isolated
adipocytes were signiﬁcantly lower than those isolated from
the other fat deposits. In OVX + EB rats, resistin mRNA lev-
els in adipocytes isolated from IG, PM, PR, RP, and PO adi-
pose tissue were, respectively, 70%, 73%, 53%, 67% and 90%
lower than the corresponding value in the OVX group
(P < 0.05).
3.3. Resistin gene expression in cultured adipocytes is
downregulated by estrogen in vitro
When adipocytes isolated from the PO adipose tissue of un-
treated non-OVX female rats were used to test the in vitro ef-
fect of estradiol on resistin gene expression, the results showed
that estradiol suppressed resistin gene expression in a time-
dependent manner (Fig. 3A). A signiﬁcant 30% decrease in res-
istin mRNA levels was detected after 4 h exposure to 107 M
estradiol, while the maximal decrease (50%) was seen after 24 h
exposure (Fig. 3A). When adipocytes from PO fat deposits
were cultured, then treated for 24 h with 1012, 1010, 108,
or 106 M estradiol, resistin mRNA levels decreased in a
dose-dependent manner, with a signiﬁcant 20% decrease being
Fig. 4. Intracellular resistin contents are lower in PM adipocytes from
OVX + EB rats than in those from OVX rats. Cell lysate from PM
adipocytes of OVX and OVX + EB rats was subjected to Western
blotting (100 lg protein per lane) using anti-resistin and anti-a-tubulin
antibodies. This blot is representative of those of three separate
experiments.
Fig. 5. Intracellular resistin contents in adipocytes are decreased by
in vitro estradiol treatment. Adipocytes isolated from the PO adipose
tissue of untreated non-OVX female rats were in vitro exposed to 107
M estradiol for 24 h. Intracellular resistin contents were measured by
Western blotting and densitometric analysis, as described in Section 2,
and normalized to the a-tubulin levels. The results are means ± S.D.
for three separate experiments, each using pooled adipocytes from six
rats. *P < 0.05 compared to the control group.
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imal decrease (50%) being seen with 108M estradiol (Fig. 3B).
3.4. Intracellular resistin contents in adipocytes are decreased
by estrogen in vivo and in vitro
The eﬀect of estrogen on adipose resistin contents, evaluated
by Western blotting, was also examined in vivo in OVX and
OVX + EB rats. In OVX + EB rats, intracellular resistin con-
tents in adipocytes isolated from PM adipose tissue were sig-
niﬁcantly lower than that in the OVX group (Fig. 4). In
addition, rat adipocytes were treated in vitro with estradiol
(107 M) or vehicle for 24 h and intracellular resistin contents
were determined. Results showed that estradiol decreased
intracellular resistin contents in cultured rat adipocytes (Fig.
5).4. Discussion
The present study demonstrated that in vivo treatment with
estrogen suppressed resistin gene expression in adipocytes iso-
lated from various white adipose tissues of OVX rats. In addi-
tion, in vitro estrogen treatment also decreased resistin gene
expression in cultured adipocytes isolated from the PO adipose
tissue of untreated non-OVX female rats. Resistin gene expres-
sion in OVX female rats was lower in adipocytes isolated fromsubcutaneous adipose tissue (IG) than in those isolated from
abdominal adipose tissues (PM, PR, RP, and PO) (Fig. 2).
In humans, more resistin is released by omental adipose tissue
than by subcutaneous adipose tissue [22]. The increased
expression of the resistin gene in central adipose tissue sup-
ports the hypothesis of a role for resistin in linking
central obesity and type 2 diabetes and/or cardiovascular
diseases [23]. Further studies are needed to investigate this
possibility.
The present study showed regional diﬀerences in the sup-
pression of resistin gene expression by estrogen in vivo. Max-
imal inhibition of resistin gene expression was seen in PO
adipocytes isolated from estrogen-treated OVX rats (Fig.
2E), showing that the eﬀect of estrogen was greater on PO
adipocytes than on adipocytes isolated from other anatomical
sites in OVX rats. Site-speciﬁc regulation of estrogen has been
discussed in several reports. An in vitro study showed that
exposure to estrogen induces a 1.4-, 1.2-, or 1.75-fold increase
in leptin mRNA levels in subcutaneous, PR, and PM adipo-
cytes, respectively [15]. Pedersen et al. [24] also reported that
estrogen lowers the lipolytic response in subcutaneous fat tis-
sue, but seems not to aﬀect lipolysis in adipocytes from the
intraabdominal fat tissue. One possible explanation for this
site-speciﬁc regulation by estrogen is the diﬀerential distribu-
tion of estrogen receptors (ERs) in various adipose tissues.
Estrogens mediate their eﬀects through two receptor isoforms,
ER-a and ER-b, each of which is responsible for diﬀerent bio-
logical functions as indicated by their tissue-speciﬁc expression
patterns. Diﬀerent roles have been assigned to ER-a and ER-b
in mediating the eﬀects of estrogen in adipose tissue. This was
suggested by the observations that ER-a gene knockout mice
develop obesity, whereas ER-b knockout mice have a normal
amount of adipose tissue [25,26], and the fact that, in human
adipocytes, ER-b mRNA levels are much lower than ER-a
mRNA levels [27]. These ﬁndings indicated that the ER-a sub-
type may play a predominant role in mediating the eﬀects of
estrogens on adipocytes.
In the present study, we found that in vivo treatment of
OVX rats with EB resulted in lower resistin gene expression
than in non-EB-treated rats (Fig. 2E) and such decreased
expression was also observed after in vitro estradiol treatment
of PO adipocytes (Fig. 3). However, the degree of the estrogen-
induced decrease in adipocyte resistin mRNA levels was higher
in vivo than in vitro, since plasma levels in the in vivo study
were about 200 pg/ml (5 · 1010 M) and gave a 90% decrease,
whereas the maximal eﬀect in vitro was seen at concentrations
of 108 and 106 M and consisted of only a 50% decrease. The
diﬀerence in resistin suppression caused by in vivo and in vitro
estrogen treatment may indicate that estrogen is not the only
factor involved in the regulation of resistin expression in vivo
in OVX + EB rats and that the decreased resistin gene expres-
sion may be due to a synergic eﬀect of estrogen and other fac-
tors. As shown in Table 1, serum insulin levels were
signiﬁcantly higher in OVX + EB rats than in OVX rats. Hau-
gen et al. [28] have shown that insulin has a marked suppres-
sive eﬀect on resistin mRNA levels in 3T3-L1 adipocytes. In
addition to estrogen, insulin may be a possible candidate inhib-
itor of resistin expression in OVX + EB rats. On the other
hand, study also demonstrated that estrogen increases adipose
leptin expression [15]. Results of recent studies showed that
leptin treatment decreases adipose resistin expression and cir-
culating resistin level in mice [29,30]. It was also possible that
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estrogen-induced leptin overexpression in vivo.
In our in vivo study, OVX + EB rats had higher insulin lev-
els, a higher HOMA-IR, and a lower glucose/insulin ratio than
OVX rats, showing that they developed hyperinsulinemia and
insulin resistance. Several lines of evidence suggest an associa-
tion between estrogen and insulin sensitivity. Estrogen has
been proposed to cause insulin resistance in 3T3-L1 adipocytes
by reducing the cellular content of insulin receptor substrate
proteins [31]. However, there is considerable evidence against
an adverse eﬀect role of estrogen on glucose metabolism and
for a beneﬁcial action of estrogen. In male mice with complete
aromatase deﬁciency, which are unable to catalyze the forma-
tion of estrogens from androgens, insulin resistance progres-
sively develops [32]. OVX mice are more insulin-resistant
than sham controls and treatment of these OVX mice with
estrogen normalizes both glucose tolerance and insulin sensi-
tivity [33]. The role of estrogen in hormone replacement ther-
apy (HRT) also needs to be settled. Despite a recent review
claiming that HRT reduces the incidence of type 2 diabetes
[34], other data do not ﬁt to this concept. For example,
HRT is reported to be associated with attenuated insulin sen-
sitivity [35] and with a worsening of coronary atherosclerosis
and exacerbation of the proﬁle of inﬂammatory markers in
women with abnormal glucose tolerance [36]. Because of these
conﬂicting results, we believe that insulin sensitivity in OVX
rats or other experimental models and in postmenopausal wo-
men may be determined by multiple factors. HRT strategies
should therefore be carefully designed and optimized to mini-
mize possible adverse eﬀects of estrogen in terms of producing
metabolic disorders.
Based on our in vivo and in vitro ﬁndings, we conclude that
estrogen downregulates adipocyte resistin mRNA expression
in a site-speciﬁc manner and that estrogen may be a pivotal
negative regulator of resistin gene expression.
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